Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
11/2002
11/28/2002WO2002094272A1 Analgesic composition and method
11/28/2002WO2002094270A2 Mip-1 alpha receptor ligands - drugs for t-cell mediated and autoimmune diseases
11/28/2002WO2002094263A2 Caspase inhibitors and uses thereof
11/28/2002WO2002094262A1 Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors
11/28/2002WO2002094261A1 Cxcr4-antagonistic drugs comprising nitrogen-containing compound
11/28/2002WO2002094248A2 Composition and use of substances for stabilising amino acids containing sulphur and/or for inhibiting the continuous formation of amino acids containing sulphur in a blood sample
11/28/2002WO2002094236A1 Delivery of antipsychotics through an inhalation route
11/28/2002WO2002094203A2 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
11/28/2002WO2002094202A2 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
11/28/2002WO2002094196A2 Method of treatment for cancers associated with elevated
11/28/2002WO2002094193A1 Methods for inhibiting angiogenesis
11/28/2002WO2002094192A2 Antibodies against tumor necrosis factor delta (april)
11/28/2002WO2002094186A2 Urazole compounds useful as anti-inflammatory agents
11/28/2002WO2002094185A2 Conjugates and compositions for cellular delivery
11/28/2002WO2002094180A2 Pharmaceutically active isoindoline derivatives
11/28/2002WO2002094176A2 Use of compounds with combined nep/mp-inhibitory activity on the preparation of medicaments
11/28/2002WO2002094019A1 Highly purified antiendotoxin compound
11/28/2002WO2002085897A8 Heterocyclic compounds for aging-related and diabetic vascular complications
11/28/2002WO2002080887A3 Timed pulse release composition
11/28/2002WO2002078745A3 Use of mglur5 antagonists in the manufacture of a medicament in the treatment of autism, mental retardation, schizophrenia
11/28/2002WO2002078629A3 Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
11/28/2002WO2002073235A3 Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
11/28/2002WO2002070563A3 Nuclear hormone receptor ligand binding domain
11/28/2002WO2002064557A9 New crystal forms of oxcarbazepine and processes for their preparation
11/28/2002WO2002062777A3 Amino ceramide-like compounds and therapeutic methods of use
11/28/2002WO2002048106A3 Isoindolin-1-one glucokinase activators
11/28/2002WO2002047711A3 Modulators of activity of g-protein-coupled receptor kinases
11/28/2002WO2002044153A8 4-6-diphenyl pyridine derivatives as antiinflammatory agents
11/28/2002WO2002024924A3 Protein phosphatases
11/28/2002WO2002020002A3 A method for treating allergies
11/28/2002WO2002015977A3 Methods and compositions for treating ige-related disease using nnt-1 inhibitors
11/28/2002WO2002008255A3 Cell cycle proteins and mitosis-associated molecules
11/28/2002WO2002000648A1 Imidazole derivatives or salts thereof and drugs containing the derivatives or the salts
11/28/2002WO2001096393A9 Nucleotide and amino acid sequences of oocyte factors for altering ovarian follicular growth in vivo or in vitro
11/28/2002WO2001095919A3 A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
11/28/2002WO2001092214A1 Carbamic acid esters as inhibitors of factor xa
11/28/2002WO2001090345A3 Methods and compositions for enhancing the delivery of a nucleic acid to a cell
11/28/2002WO2001089542A3 Composition for improving the cell protection comprising a lipophilic antioxidant and a hydrophilic antioxidant
11/28/2002WO2001082897A3 Liposome drug delivery
11/28/2002WO2001018021A9 B7-like polynucleotides, polypeptides, and antibodies
11/28/2002US20020178459 Genetically engineered mammal for use in the treatment of muscle and liver disorders
11/28/2002US20020178135 Image searching system and image searching method, and a recording medium storing an image searching program
11/28/2002US20020177723 Compounds and methods for the treatment of inflammatory and immune disorders
11/28/2002US20020177717 Compounds and methods for the inhibition of the expression of VCAM-1
11/28/2002US20020177707 Aminoaryl oxazolidinone n-oxides
11/28/2002US20020177689 Compounds for the treatment of sexual dysfunction
11/28/2002US20020177622 Neuroprotectants; enhancing cognition
11/28/2002US20020177618 ERK (extracellular signal regulated kinase) inhibitors for treatment of cancer, inflammatory disorders, restenosis, and cardiovascular disease
11/28/2002US20020177615 Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones
11/28/2002US20020177614 Preventing neural tissue damage caused by adenosine-diphosphate- ribosylation of eucaryotic elongation factor-2 (EF-2)
11/28/2002US20020177609 Fatty alcohol drug conjugates
11/28/2002US20020177605 3-substituted isoquinolin-1-yl derivatives
11/28/2002US20020177604 N-(4-chlorobenzyl)-6-(3-hydroxy-1-propynyl)-1-7-dimethyl-4-oxo-1,4 -dihydro(1,8)naphthyridine-3-carboxamide for example; inhibiting viral DNA polymerase; treating herpes virus infections
11/28/2002US20020177603 5,10-dihydrobenzo(b)(1,8)naphthyridine compounds, N-oxides; 3,7-Dichloro-5-isopropoxymethyl-5-trifluoromethyl-5,10 -dihydrobenzo(b)(1,8)naphthyridine for example; combination therapy
11/28/2002US20020177598 Inhibit activity of chemokines, macrophage inflammatory protein-1 (MIP-1 alpha) and RANTES; 1-((4-chlorophenoxy)methyl)-carbonyl-2-methyl-4-(4-fluorobenzyl)piperazine for example
11/28/2002US20020177596 2,3,4,4a,5,6-hexahydro-1H-pyrazino(1,2-a)quinoxaline derivatives; treating depression, schizophrenia; (5-hydroxytryptamine=5HT) 5HT2a antagonist or a 5HT2c agonist
11/28/2002US20020177587 Treating sexual dysfunction including erectile dysfunction, diabetes melitus, gastrointestinal disorders, including gastric paresis and cardiovascular disorders; cyclic guanosine 3',5'-monophosphate (cGMP)
11/28/2002US20020177565 Toso proteins and related molecules which have an inhibitory effect on TNF mediated apoptosis
11/28/2002US20020177552 Colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions; alternatively, antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a
11/28/2002US20020177545 Compositions and methods for treating gonadotrophin related illnesses
11/28/2002US20020177187 Nucleotide sequences coding polypeptide for use in the treatment of nervous system disorders
11/28/2002US20020177145 Detection and classification of nervous system progenitor cells; obtain tissue, monitor expression of daedalos protein in sample, compare to control, ampified daedalos expression indicates presence of nervous system progenitor cells
11/28/2002US20020176856 Administering an antibody to the mammal, that binds with a specified target epitope of an antigen, associated with a tumor or an infectious agent; having engineered glycosylation site in the constant region of the heavy chain antibodies
11/28/2002US20020176852 Mitogenic oxygenase regulators
11/28/2002US20020176818 Radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid
11/28/2002DE10124867A1 New substituted (hetero)aryl-alkenes or -alkynes, used as thrombin inhibitors, serine protease inhibitors, antithrombotic agents and intermediates
11/28/2002DE10123586A1 New 3,5-diamino-1,2,4-triazole derivatives, are cyclin dependent kinase inhibitors useful for treating e.g. cancer, autoimmune, cardiovascular or neurodegenerative diseases or viral infections
11/28/2002DE10122140A1 Rekombinante Fusionsproteine und deren Trimere Recombinant fusion proteins and their trimers
11/28/2002CA2489768A1 Methods for preparation and use of psorospermin analogs
11/28/2002CA2450535A1 Tri-and tetraaza-acenaphthylen derivatives as crf receptor antagonists
11/28/2002CA2449442A1 Combination medicament for treatment of neoplastic diseases
11/28/2002CA2448253A1 Human cdnas and proteins and uses thereof
11/28/2002CA2448186A1 Novel smg-1
11/28/2002CA2448174A1 Compounds capable of modulating the activity and stimulating the production of a catalytic antibody
11/28/2002CA2448102A1 Novel mixed lineage kinase (7) (mlk7) polypeptide, polynucleotides encoding the same, and methods of use thereof
11/28/2002CA2448084A1 Aza hydroxylated ethyl amine compounds
11/28/2002CA2448080A1 Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
11/28/2002CA2448076A1 3-quinoline-2-(1h)-ylideneindolin-2-one derivatives
11/28/2002CA2448022A1 Compositions for protein delivery via the pulmonary route
11/28/2002CA2447940A1 Urazole compounds useful as anti-inflammatory agents
11/28/2002CA2447883A1 Use of nf-kappa-b inhibitors to treat dry eye disorders
11/28/2002CA2447671A1 Trisubstituted-n-[(1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors
11/28/2002CA2447598A1 Use of compounds with combined nep/mp-inhibitory activity in the preparation of medicaments
11/28/2002CA2447231A1 Methods for inhibiting angiogenesis
11/28/2002CA2447180A1 Herbal compositions for the treatment of mucosal lesions
11/28/2002CA2447161A1 Conjugates and compositions for cellular delivery
11/28/2002CA2447103A1 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
11/28/2002CA2447066A1 Method of treatment for cancers associated with elevated
11/28/2002CA2447023A1 Conjugates activated by cell surface proteases and therapeutic uses thereof
11/28/2002CA2447020A1 The use of 4-aminopyridine derivatives for the treatment of mglur5 receptor mediated diseases
11/28/2002CA2446734A1 Antibodies against tumor necrosis factor delta (april)
11/28/2002CA2446516A1 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
11/28/2002CA2446510A1 Therapeutic agent for tumor of neural origin
11/28/2002CA2446332A1 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
11/28/2002CA2446331A1 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
11/28/2002CA2446155A1 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders
11/28/2002CA2446154A1 4-(penyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
11/28/2002CA2446049A1 The use of a gatran for the manufacture of a medicament for the treatment of pulmonary fibrosis
11/28/2002CA2445972A1 Methods and compositions for treating respiratory mucin production associated disease conditions
11/28/2002CA2445631A1 Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same
1 ... 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 ... 1564